Literature DB >> 14646525

Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines.

P Perego1, S C Righetti, R Supino, D Delia, C Caserini, N Carenini, B Bedogné, E Broome, S Krajewski, J C Reed, F Zunino.   

Abstract

Since apoptosis is the primary mode of cell death induced by cisplatin, the role of apoptosis and apoptosis-related gene products in cisplatin resistance was investigated in four human cisplatin-resistant cell lines of different tumour type. A common feature of the resistant sublines was a reduced susceptibility to drug-induced apoptosis compared to parental sensitive lines. Loss of wild-type p53 function was not a general event associated with the development of drug resistance. An increased bcl-2 expression was found in resistant cells characterized by mutant p53 (A431/Pt and IGROV-1/Pt), whereas in osteosarcoma (U2-OS/Pt) and in ovarian carcinoma (A2780/CP) cells with wild-type p53, bcl-2 levels were markedly reduced. U2-OS/Pt cells had a 16-fold increase in the level of Bcl-xL protein. Stable transfection of U2-OS cells with bcl-xL cDNA conferred a low level of drug resistance to cisplatin, suggesting that overexpression of this gene contributes to the cisplatin-resistant phenotype of this osteosarcoma cell system. In conclusion, these observations suggest a variable contribution of apoptosis-related genes to cisplatin resistance depending on the biological background of the cell system and presumably reflecting different pathways of apoptosis.

Entities:  

Year:  1997        PMID: 14646525     DOI: 10.1023/a:1026442716000

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  11 in total

1.  Apoptosis-related mRNA expression profiles of ovarian cancer cell lines following cisplatin treatment.

Authors:  Joohee Yoon; Eung-Sam Kim; Sung Jong Lee; Chang-Wook Park; Hyung Jin Cha; Bee Hak Hong; Kwan Yong Choi
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

Review 2.  Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.

Authors:  S Wu; R K Singh
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

3.  Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.

Authors:  Ganna V Kalayda; Bart A J Jansen; Peter Wielaard; Hans J Tanke; Jan Reedijk
Journal:  J Biol Inorg Chem       Date:  2005-04-12       Impact factor: 3.358

4.  Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.

Authors:  F Andriani; P Perego; N Carenini; G Sozzi; L Roz
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

Review 5.  Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Authors:  Min H Kang; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

6.  A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Authors:  G Pratesi; P Perego; D Polizzi; S C Righetti; R Supino; C Caserini; C Manzotti; F C Giuliani; G Pezzoni; S Tognella; S Spinelli; N Farrell; F Zunino
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

7.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

8.  Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.

Authors:  P Zhang; P Zhang; B Shi; M Zhou; H Jiang; H Zhang; X Pan; H Gao; H Sun; Z Li
Journal:  Cell Death Dis       Date:  2014-01-09       Impact factor: 8.469

9.  Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition.

Authors:  Bernd Kubista; Thomas Schoefl; Lisa Mayr; Sushilla van Schoonhoven; Petra Heffeter; Reinhard Windhager; Bernhard K Keppler; Walter Berger
Journal:  J Exp Clin Cancer Res       Date:  2017-04-12

10.  The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.

Authors:  Gabriele Romano; Ludovica Santi; Maria Rosaria Bianco; Maria Rita Giuffrè; Mariateresa Pettinato; Cristina Bugarin; Cristina Garanzini; Leonilde Savarese; Silvia Leoni; Maria Grazia Cerrito; Biagio Eugenio Leone; Giuseppe Gaipa; Emanuela Grassilli; Michele Papa; Marialuisa Lavitrano; Roberto Giovannoni
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.